Karteolol

Karteolol
(IUPAC) ime
	(RS)-5-[3-(tert-butilamino)-2-hidroksipropoksi]-3,4-dihidrohinolin-2(1H)-on
Klinički podaci
Robne marke	Ocupress
AHFS/Drugs.com	Mikromedeks, detaljne potrošačke informacije
MedlinePlus	a601078
Identifikatori
CAS broj	51781-06-7
ATC kod	C07AA15 S01ED05
PubChem	2583
DrugBank	DB00521
ChemSpider	2485
UNII	8NF31401XG
KEGG	D07624
ChEBI	CHEBI:3437
ChEMBL	CHEMBL839
Hemijski podaci
Formula	C16H24N2O3
Mol. masa	292,373 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) ; Key: LWAFSWPYPHEXKX-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	85%
Metabolizam	Hepatički, aktivan sa 8-hidrokarteololom
Poluvreme eliminacije	6–8 sati
Izlučivanje	Renalno (50-70%)
Farmakoinformacioni podaci
Trudnoća	C(US)
Pravni status	℞ Prescription only
Način primene	Kapi za oči

Karteolol - trgovački nazivi Cartrol, Ocupress, Teoptic, Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Poenglaucol, Singlauc - je a neselektivni beta blokator koji se upotrebljava za liječenje glaukoma. Ovaj beta-blokator ima unutrašnju simpatomatsku aktivnost. Djelujući na srčane β₁- i β₂receptore karteolol smanjuje broj otkucaja i kontraktilnost srca za atrio-ventrikularno provođenje signala i aktivnost na relaciji plazma - renin. Stoga je pogodan za liječenje srčane aritmije i angine.^[6] Očni pritisak regulira smanjenjem proizvodnje vodice što ga čini djelotvornim u liječenju glaukoma.

Tačan mehanizam djelovanja nije poznat.

Lijek je je patentirala kompanija Otsuka Pharmaceutical, 1973. godine. Karteolol dalje smanjuje očni pritisak smanjenjem proizvodnje oristi.

Nekomercijalni uredi

Arteoptic^® (Novartis)
Endak^® (Madaus)

Povezano uredi

Beta blokator

Literatura uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Šablon:RömppOnline

Dodatna literatura uredi

El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). „Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.”. Drug Deliv 13 (1): 55–9. DOI:10.1080/10717540500309073. PMID 16401594.
Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). „Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.”. Cornea 24 (2): 213–20. DOI:10.1097/01.ico.0000141232.41343.9d. PMID 15725891.
Trinquand C, Romanet J, Nordmann J, Allaire C (2003). „[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]”. J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.

Vanjski linkovi uredi

El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). „Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.”. Drug Deliv 13 (1): 55–9. DOI:10.1080/10717540500309073. PMID 16401594.
Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). „Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.”. Cornea 24 (2): 213–20. DOI:10.1097/01.ico.0000141232.41343.9d. PMID 15725891.
Trinquand C, Romanet J, Nordmann J, Allaire C (2003). „[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]”. J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Šablon:RömppOnline

[6]

[1]

[2]

[3]

[4]

[5]